Melanoma Cancer section

Melanoma News & Features

Obesity, Male Gender May Improve Survival Outcomes with Targeted and Immunotherapy in Melanoma

Obesity, Male Gender May Improve Survival Outcomes with Targeted and Immunotherapy in Melanoma

A retrospective study evaluated the relationship of BMI with survival outcomes among patients with metastatic melanoma who received targeted therapy, immunotherapy, or chemotherapy.

FDA Upgrades Nivolumab to Regular Approval for Adjuvant Treatment of Advanced Melanoma

FDA Upgrades Nivolumab to Regular Approval for Adjuvant Treatment of Advanced Melanoma

The FDA granted approval for nivolumab for adjuvant treatment of some patients with melanoma, based on the results of the CHECKMATE-238 study.

Potential for Metastatic Melanoma Cure Seen in High CR Rate With Pembrolizumab

Potential for Metastatic Melanoma Cure Seen in High CR Rate With Pembrolizumab

Baseline tumor size and PD-L1 status were independently associated with the likelihood of a complete response.

Distinct Patterns of Shiny White Streaks Strong Indicator of Melanoma

Distinct Patterns of Shiny White Streaks Strong Indicator of Melanoma

Patients presenting with lesions with shiny white streaks on dermoscopy should undergo biopsy for possible melanoma.

Melatonin Derivatives Exhibit Cytotoxic Activity in Melanoma and Breast Cancer

Melatonin Derivatives Exhibit Cytotoxic Activity in Melanoma and Breast Cancer

Melatonin and its analogues, in addition to their ability to regulate circadian rhythms, may exhibit cytotoxic activity via various cellular mechanisms.

No Increased Risk for Melanoma in Patients With MM

No Increased Risk for Melanoma in Patients With MM

An increased prevalence of melanoma has been observed in patients with various immunocompromised conditions.

Researchers Find No Link Between Acne and Malignant Melanoma in Men

Researchers Find No Link Between Acne and Malignant Melanoma in Men

Individuals categorized as overweight or obese had a significantly increased risk for malignant melanoma.

Survival Benefit in Advanced Melanoma With Pembrolizumab Versus Ipilimumab

Survival Benefit in Advanced Melanoma With Pembrolizumab Versus Ipilimumab

Fifty-five percent of patients treated with pembrolizumab survived through 24-months compared with 43% of patients treated with ipilimumab.

Challenging the Standard of Care in Advanced Melanoma: Focus on Pembrolizumab

Challenging the Standard of Care in Advanced Melanoma: Focus on Pembrolizumab

[Cancer Management and Research] This study examines the advances that pembrolizumab has made in melanoma and upcoming research that may further improve melanoma treatment.

Case Report of a KIT-mutated Melanoma Patient With an Excellent Response to Apatinib and Temozolomide Combination Therapy

Case Report of a KIT-mutated Melanoma Patient With an Excellent Response to Apatinib and Temozolomide Combination Therapy

[OncoTargets and Therapy] This article examines a case of metastatic melanoma in which the patient had an excellent response to apatinib/TMZ combination therapy with progression-free survival for more than one year.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs